JPH0250426B2 - - Google Patents
Info
- Publication number
- JPH0250426B2 JPH0250426B2 JP56083736A JP8373681A JPH0250426B2 JP H0250426 B2 JPH0250426 B2 JP H0250426B2 JP 56083736 A JP56083736 A JP 56083736A JP 8373681 A JP8373681 A JP 8373681A JP H0250426 B2 JPH0250426 B2 JP H0250426B2
- Authority
- JP
- Japan
- Prior art keywords
- hepatitis
- serum
- substance
- present
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000006454 hepatitis Diseases 0.000 claims description 67
- 231100000283 hepatitis Toxicity 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 31
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 210000004185 liver Anatomy 0.000 claims description 16
- 239000000032 diagnostic agent Substances 0.000 claims description 10
- 229940039227 diagnostic agent Drugs 0.000 claims description 10
- 238000011888 autopsy Methods 0.000 claims description 8
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 claims description 8
- 238000004062 sedimentation Methods 0.000 claims description 8
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 238000002523 gelfiltration Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 102000006395 Globulins Human genes 0.000 claims description 4
- 108010044091 Globulins Proteins 0.000 claims description 4
- 239000011543 agarose gel Substances 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 description 48
- 210000002966 serum Anatomy 0.000 description 40
- 239000000243 solution Substances 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 210000003743 erythrocyte Anatomy 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 206010019799 Hepatitis viral Diseases 0.000 description 7
- 210000000601 blood cell Anatomy 0.000 description 7
- 208000002672 hepatitis B Diseases 0.000 description 7
- 201000001862 viral hepatitis Diseases 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000004520 agglutination Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 230000035931 haemagglutination Effects 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 5
- 239000001263 FEMA 3042 Substances 0.000 description 5
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 5
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000007975 buffered saline Substances 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000003127 radioimmunoassay Methods 0.000 description 5
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 5
- 229940033123 tannic acid Drugs 0.000 description 5
- 235000015523 tannic acid Nutrition 0.000 description 5
- 229920002258 tannic acid Polymers 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 208000005252 hepatitis A Diseases 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010019791 Hepatitis post transfusion Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000000432 density-gradient centrifugation Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- -1 for example Proteins 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 238000000760 immunoelectrophoresis Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000271566 Aves Species 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000007982 barbital buffer Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960002520 hepatitis vaccine Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
æ¬çºæã¯ééåèçé¢é£æåããã³èšºæè¬
ã«é¢ãããããã«è©³ããã¯ãééåèçé¢é£
æåããã³åœè©²æåã®çµåäœäžŠã³ã«ããããäž»èŠ
ãªæ§ææåãšããŠå«æããééåèç蚺æè¬
ã«é¢ããã ãŠã€ã«ã¹èçã«ã€ããŠã¯åŸæ¥ããåããã³ïŒ¢
åã®ååšãç¥ãããŠããããã§ã«é¢é£æåæäœç³»
ãæããã«ããããããå©çšããå ç«è¡æž åŠçãª
蚺æãå¯èœãšãªããããã«ã¯ã¯ãã³ã®éçºãå°å ¥
ã«ãŸã§è³ã€ãŠããã ããããªãããããã«äŒŽã€ãŠééåèçã
ããªãã¡ãåŸæ¥ããç¥ãããŠããåèçããã³
åèçã®ãããã«ãå±ããªããŠã€ã«ã¹èçã®å
åšãç¥ãããããã«ãªããããããã®çºçé »åºŠã
äºæ³ä»¥äžã«é«ãããšãæãããšãªã€ãŠæ¥ããäŸã
ã°ã茞è¡åŸèçã®80ã90ïŒ ãããã¯ããã«ãã以
äžã®ãã®ãééåèçã§ãããæ£çºçã«çºç
ããæ¥æ§èçã«ã€ããŠãçŽ50ïŒ ã¯ééåèç
ã§ããããšãå ±åãããã«è³ã€ãŠããããŸãæ£åžž
äŸè¡è ã®äžã«ããééåèçãŠã€ã«ã¹ã®ä¿æ
è ãããªãã®æ°ååšããããšãæãããšãªã€ãŠæ¥
ãã以äžã«èšèŒããæç®ã¯ééåèçã«é¢ã
ãäžè¿°ã®ç¶æ³ãå ±åãããã®ã§ãããåèã®ãã
ã«åæããã (1) PrinceãA.M.et al.ïŒLongâincubation
postâtransfusion hepatitis without
serological evidence of exposure to
hepatitisâ virus.Lancet.ïŒ241â246ã
1974. (2) AlterãH.J.et al.ïŒClinical and
serological analysis of transfusionâ
associated hepatitis.Lancet.ïŒ838â841ã
1975. (3) FeinstonsãS.M.et al.ïŒTransfusionâ
associated hepatitis not due to viral
hepatitis type  or B.N.Engl.J.Med.292ïŒ
767â770ã1975. (4) MeyersãJ.D.et al.ïŒParenterally
transmitted nonâãnonâ hepatitis.
Ann.Intern.Med.87ïŒ57â59ã1977. (5) VillarejosãV.M.et al.ïŒEvidence for
viral hepatitis other than type  or type
 among persons in Costa Rica.N.Engl.J.
Med.293ïŒ1350â1352.1975. (6) DienstagãJ.L.et al.ïŒEtiology of
sporadic hepatitis  surface antigenâ
negative heâpatitis.Ann.Intern.Med.87ïŒïŒ
âïŒã1977. ããŠãããã§ééåèçãšã¯ïŒ¡åèçãŠã€
ã«ã¹ãåèçãŠã€ã«ã¹ããµã€ãã¡ã¬ããŠã€ã«
ã¹ããšãã¹ã¿ã€ã³ããŒãŠã€ã«ã¹ãªã©åŸæ¥ç¥ããã
ãŠã€ã«ã¹ä»¥å€ã®ãŠã€ã«ã¹ãç åäœãšããŠé¢äžãã
ããšã«ããçºçãããšèããããèçã§ãã€ãŠã
HAæäœãHBsæäœãHBcæäœãHBeæäœã«ã€
ããŠææã®äžæãèªããããªããã®ãèšããåŸã€
ãŠãééåèçæ£è ãšã¯ãèçãŠã€ã«ã¹ã«èµ·
å ããèçæ£è ã§ãã€ãŠïŒ¡åèç蚺æããã³ïŒ¢å
èç蚺æã«ãããŠé°æ§ã瀺ããåèçããã
åèçãããé€å€ãããæ£è ã§ãããšå®çŸ©ãã
ããäžè¬ã«ééåèçã§ã¯ãåèçã«æ¯èŒ
ãããšèŒžè¡ããçºçãŸã§ã®å¹³åæœäŒæãçãããŸ
ãGPTã®æ倧å€ãäœããšããåŸåãããããã
ããã®åé¢ãæç¶æ§ããããäŸãã°GPTç°åžžã¯
æ ¢æ§åããŠããªãã®é·æéã«åã¶ãšããç¹åŸŽãã
ãããããããããã«ãããééåèçã¯èŒž
è¡åŸèçã®å€§éšåãå ããŠããããã€ééå
èçãŠã€ã«ã¹ãåå ãšãªãèçŸæ£ã¯è硬å€ãèç
ãªã©åºç¯å²ã«åãã§ãããé©åãªã察å¿çãæ©æ¥
ã«éçºãããããšãæãŸããŠããã®ã§ããããã
ãã«ãééåèçã«ã€ããŠã¯ãæªã ãã®ãŠã€
ã«ã¹æ¬æ ãããã¯ããã«é¢é£ããæåæäœç³»ã確
ç«ãããŠããããåŸã€ãŠé©åãªã蚺æããã³ã¯ã¯
ãã³ã®è£œé ããªãããŠããªãã®ãçŸç¶ã§ããã ééåèçé¢é£æåã«é¢ããå è¡æè¡ãšã
ãŠã¯ç¹éæ55â122156å ¬å ±ã«èšèŒãããçºæãã
ããHCæåãšåœåãããç©è³ªã®æäŸãé瀺ãã
ãŠããããããããã®HCæåã¯ãã€ã±ãåè
çå埩ææ£è ã®è¡æŒ¿ãŸãã¯è¡æž ãšã®éã«ãããŠæ
åæäœåå¿ãçããç¹ã«ç¹åŸŽããããééå
èçã«ãããåºãäžè¬åããåå¿æ§ã瀺ãã«è³ã€
ãŠããªãããŸãåœè©²HCæåãåé¢ç²Ÿè£œãããã
ã®åºçºç©è³ªãšããŠã¯HBsæåé°æ§è¡æ¶²ã茞è¡ã
ãã®ã¡ã«èçãçºçããGPTã®äžæãäºå³°æ§ãŸ
ãã¯ãã以äžã®å€å³°æ§ã瀺ãããã€æœäŒæã®æ¯èŒ
çé·ãæ£è 矀ã®æ¥æ§æè¡æŒ¿ãŸãã¯è¡æž ãéžæããŠ
䜿çšããå¿ èŠããããåºçºç©è³ªãšããŠã®éå®æ¡ä»¶
ãããªãå€ããšããæ¬ ç¹ãããã ãããå®æ ã«ãããã¿ãæ¬çºæè ã¯ééå
èçã«ã€ããŠäžè¬çã§ããããã€ééåèç
ã«ç¹ç°çã§ããé¢é£æåãç©è³ªãšããŠåé¢ããã
ãšãè©Šã¿ããã®çµæãééåèçåæ€èãã
ã®åé¢ç²Ÿè£œã«ããææã®ç©è³ªãååŸããããšã«æ
åããæ¬çºæãå®æããã«è³ã€ãã æ¬çºæç©è³ªã¯ééåèçåæ€èããåé¢ç²Ÿ
補ããããã®çååŠçæ§ç¶ã¯ä»¥äžã®ããšãã§ã
ããååéã¯ã²ã«éæ³ã«ããæ±ãããš150äžä»¥
äžã§ãããæ²éå®æ°ïŒ10-13ïŒã¯Beckmann
Model ã§æž¬å®ãããš51.5Sã瀺ããå¡©åã»ã·ãŠ
ã ãŸãã¯èåã«ãªãŠã 溶液äžã®æµ®äžå¯åºŠïŒïœïŒ
cm3ïŒã¯ã¢ããã®å±æèšã«ãã€ãŠæ±ãããš1.15ã
1.25ã§ãããç²åçŽåŸïŒïœïœïŒã¯é»åé¡åŸ®é¡èŠ³å¯
ã«ãããš26ã37ïŒå¹³å31.5ïŒã§ãããé»æ°ç移å
床ã¯å ç«é»æ°æ³³åæ³ã«ããæ±ãããšÎ±2âα1ã°ãã
ãªã³ã®é åã§ããã 以äžããæãããªããšããæ¬çºæç©è³ªã¯åºçºç©
質䞊ã³ã«çååŠçæ§ç¶ã«ãããŠç¹éæ55â122156
å ¬å ±ã«èšèŒã®HCæåãšã¯ç°ãªãç©è³ªã§ããããš
ãç¥ãããã ãŸãæ¬çºæç©è³ªã¯åŸèšå®éšäŸã«ç€ºãããããšã
ééåèçå埩ææ£è è¡æž ããã³é »å茞è¡æŽ
ã®ããæ£è ã®è¡æž ãšã®éã«å¯å€©ã²ã«å ã®æ²éåå¿
ã瀺ãããŸãæ¬çºæç©è³ªãæäœããçŸèµ€è¡çã¯é
éåèçæ£è ã®å埩æè¡æž ãšã®éã«ç¹ç°çã«
ãããé«æ床ã§å身赀è¡çåéåå¿ã瀺ãããã®
åé¢ãæ¬çºæç©è³ªã¯HAæäœãHBsæäœãHBeæ
äœãHBcæäœãÎŽæäœãHCæäœãEBæäœã
Araiæäœãæäœãæ£åžžããèäžæž æäœããã
ã³åçš®ã®æ£åžžããè¡æŒ¿æäœã®ããããšãåå¿ã瀺
ããªãã€ããåŸã€ãŠãæ¬çºæç©è³ªã¯ééåè
çã«ã€ããŠäžè¬çã§ããããã€ééåèçã«
ç¹ç°çãªé¢é£æåãšããŠæçšãªç©è³ªã§ããããšã
å€æãããäŸãã°å®éšäŸïŒã«ç€ºãããšãéé
åèççç¶ã®çµé蚺æã«ãããŠæ£ç¢ºãªæ å ±ãæäŸ
ããäžã§æçšã§ããã ãŸãæ¬çºæç©è³ªãé©åœãªãã¢ãžãŠãã³ããäŸã
ã°ããã€ã³ãå®å šã¢ãžãŠãã³ããšå ±ã«å®¶å ã«é »å
æäžããããšã«ããæ¬çºæç©è³ªã«å¯Ÿããå ç«æäœ
ãç£çããããããšãå¯èœã§ãããåŸã€ãŠãæ¬çº
æç©è³ªã¯ééåèçã¯ã¯ãã³ã®è£œé ã®çŽ æãš
ããŠããã®æçšæ§ãæåŸ ããããã®ã§ããã 次ã«æ¬çºæç©è³ªã¯ééåèçåæ€èãåºçº
ç©è³ªãšããŠéåžžã®ã¿ã³ãã¯åå粟補æ³ãäŸãã°å¯
床åŸé é å¿åé¢æ³ãå¡©ææ³ãé»æ°æ³³åæ³ãã²ã«
éæ³ãã¢ãã€ããã€ãŒã¯ãããã°ã©ãã€ãŒæ³ãç
é»ç¹ååæ³ãéå€éæ³ãã³ãŒã³ã®ååæ³ãé©å®
çµåãããŠååŸããããšãã§ããã奜ãŸããå®æœ
äŸã®æŠèŠããã€ãŠèª¬æããã°ããŸãåæ€èãã¢ãž
ããŒãäžæž ã«ã€ããŠäŸãã°ã»ãã¢ã¯ãªã«ïŒ³â200
ãçšããŠã«ã©ã ã¯ãããã°ã©ãã€ãŒååãè¡ãã
åŸãããæåéœæ§ãã©ã¯ã·ãšã³ãéå€éããŠå
å§æ¿çž®ããæåŸã«è¶ é å¿åé¢ãšéæãç¹°è¿ããã
ãã§è¶ é å¿åé¢ã«ã¯èç³æ¿åºŠåŸé é å¿ããã³å¡©å
ã»ã·ãŠã å¯åºŠåŸé é å¿ãçµåãããŠäžåãªããæ°
åè¡ãã®ã奜ãŸãããåŸããã粟補ç©ã¯å¯å€©ã²ã«
å åå¿ã«ããééåèçå埩æè¡æž ãšã®éã«
æçãªäžæ¬ã®æ²éç·ã瀺ãã粟補åã®åæ€èãã¢
ãžããŒãäžæž ã«ãããæ²éç·ãšå®å šã«èåããã
ãšã確èªããããã€ãŸããæ¬çºæç©è³ªã¯ãæ¬çºæ
ã«ä¿ãåé¢ç²Ÿè£œæ³ã«ãã€ãŠå ç«åŠçæ§ç¶ãæãã
ãšãªãåé¢ãããããšã確èªãããã®ã§ããã 次ã«æ¬çºæç©è³ªãäž»èŠãªæ§ææåãšããŠå«æã
ã蚺æè¬ã¯æ¡çšããå ç«åŠçæ€åºæ¹æ³ã«å¿ããŠé©
å®èª¿è£œããã°ãããäŸãã°æ€åºæ¹æ³ãšããŠãªã¯ã¿
ãããŒæ³ïŒMOïŒãå ç«é»æ°æ³³åæ³ïŒIESãIEPïŒã
è£äœçµååå¿æ³ïŒCFïŒãå ç«ç²çè¡çåéåå¿æ³
ïŒIAHAïŒãäžå å¹³æ¿å ç«æ¡æ£æ³ïŒSRIDïŒãå©çš
ããå Žåã«ã¯æ¬çºæç©è³ªããã®ãŸãŸäœ¿çšããŠé©åœ
ãªåœ¢æ ã«èª¿è£œããã°ãããäžäŸãšããŠäžå å¹³æ¿å
ç«æ¡æ£æ³ãå©çšããå Žåã瀺ãã°ãæ¯æäœãšããŠ
å¯å€©ãã¢ã¬ããŒã¹ããã³ãã³ãããªã¢ã¯ãªã«ã¢ã
ãã²ã«çã®äžããé©åœãªãã®ãéžã³ããããç·©è¡
液ã«å ç±æº¶è§£ãã次ã«æ¬çºæç©è³ªãæ·»å æ··åãã
åŸããã溶液ãã¬ã©ã¹æ¿äžãããã¯ãã©ã¹ããã¯
容åšå ã«æµãå·åŽåºåããåºåããã²ã«å¹³æ¿ã«è¢«
æ€è¡æž æ³šå ¥çšã®åããããã°ããã ãããã«ãæ€åºæ¹æ³ãšããŠè¡çåéåå¿æ³
ïŒPHAïŒãæŸå°æ§å ç«æž¬å®æ³ïŒRIAïŒãé µçŽ æäœæ³
ïŒELISAïŒçãå©çšããå Žåã«ã¯æ¬çºæç©è³ªã«é©
åœãªãå å·¥åŠçãæœãå¿ èŠããããããªãã¡è¡ç
åéåå¿æ³ïŒPHAïŒãå©çšããå Žåã«ã¯æ¬çºæ
ç©è³ªã埮å°ç²åã«çµåãããå¿ èŠãããã埮å°ç²
åãšããŠã¯åºä¹³é¡ããã³é³¥é¡ã®è¡çã奜ãŸãã
ãããã®ä»ãããªã¹ãã¬ã³ã©ããã¯ã¹ãããªãšã¹
ãã«ã©ããã¯ã¹ãå¡©åããã«ããã³ããã€ããã¬
ã©ã¹ããŒãºçã®çŽïŒã10ÎŒã®ç²åã䜿çšããããš
ãã§ãããæ¬çºæç©è³ªãšåŸ®å°ç²åãçµåãããã«
ã¯ãäŸãã°ã°ã«ã¿ãŒã«ã¢ã«ãããããã«ã ã¢ã«ã
ãããã¿ã³ãã³é žããã¹ãžã¢ãŸãã€ãºãã³ããž
ã³ãå¡©åã¯ãã ãã«ã«ããžã€ãããªã©ã䜿çšãã
ã°ããã æŸå°æ§å ç«æž¬å®æ³ïŒRIAïŒãå©çšããå Žåã«ã¯
æ¬çºæç©è³ªãã¢ã€ãœããŒãã§ã©ãã«åããå¿ èŠã
ãããã¢ã€ãœããŒããšããŠã¯ 125Iã 131Iã䜿çš
ããããšãã§ããã¯ãã©ãã³ïŒŽæ³ã«ããçµåãã
ãã°ããã é µçŽ æäœæ³ïŒELISAïŒãå©çšããå Žåã«ã¯ã
æ¬çºæç©è³ªãé µçŽ ãšçµåãããå¿ èŠããããé µçŽ
ãšããŠã¯ãäŸãã°ã°ã«ã³ãŒã¹ãªãã·ããŒãŒãã¢ã«
ã«ãªãã¹ãã¢ã¿ãŒãŒããã«ãªãã·ããŒãŒãããŒã¿
ãŒã¬ã©ã¯ãã·ããŒãŒçã䜿çšããããšãã§ããã
çµåå€ãšããŠã¯ã°ã«ã¿ãŒã«ã¢ã«ãããã䜿çšãã
ã°ããã æ¬çºæ蚺æè¬ã¯ééåèçã®èšºæã®ããã«
䜿çšããããããã®ã»ãã«ééåèçæäœã®
è©Šéšçãªæ€åºçšè©Šè¬ãããã¯å®éçšè©Šè¬ãšããŠã
䜿çšããããšãã§ããããšã¯ãã¡ããã§ãããåŸ
ã€ãŠãæ¬çºæã®èšºæè¬ã¯ãã®çšèªãç矩ã«è§£éã
ããã®ã«éå®ããããã®ã§ã¯ãªãã æ¬çºæç©è³ªããã³èšºæè¬ã®æçšæ§ã以äžã«èšèŒ
ããå®éšäŸããã€ãŠèª¬æããã å®éšäŸ ïŒ è©Š æ  æ¬çºæç©è³ª  ééåèçå埩ææ£è ã®è¡æž ãã®äž  ééåèçå埩ææ£è ã®è¡æž ãã®äº  é »å茞è¡æŽã®ããæ£è ã®è¡æž  æ£åžžããè¡æž  æ£åžžããèãã¢ãžããŒãäžæž æ¹ æ³ ã¢ã¬ããŒã¹ïŒ¡â45ïŒåäºååŠïŒ0.8ïŒ ïŒïœïŒïœïŒã
EDTAã»3Na0.02Mãå¡©åãããªãŠã 0.1Mã
NaN30.1ïŒ ãããªã¹å¡©é žç·©è¡æ¶²ïŒ0.01MãPH7.5ïŒ
ã«æº¶è§£ããåã1.5mmã®å¯å€©ã²ã«å¹³æ¿ãäœè£œãã
è©Šæã«ã€ããŠãã€ã¯ããªã¯ã¿ãããŒæ³ã«ããæ€åº
ãã¹ãããããªã€ãã çµ æ çµæãå³ïŒã«ç€ºããå³ïŒããæãããªããšãæ¬
çºæç©è³ªã¯ééåèçå埩ææ£è ã®è¡æž ãã
ã³é »å茞è¡æŽã®ããæ£è ã®è¡æž ãšæ²éç·ãçæ
ãããããã¯å®å šã«èåããŠããããšã確èªãã
ããåŸã€ãŠããããã¯å ç«åŠçã«åäžã®ç¹ç°æ§ã
æããæåæäœç³»ã§ããããšãå€æããããŸãã
ã®æåæäœç³»ã¯æ£åžžããè¡æž ããã³æ£åžžããèã
ã¢ãžããŒãäžæž ãšã®äº€å·®åå¿ããŸã€ãã瀺ããŠã
ãªãã å®éšäŸ ïŒ è©Š æ çŸèµ€è¡çãã°ã«ã¿ãŒã«ã¢ã«ããã溶液ã§åºå®
ããã¿ã³ãã³é žæº¶æ¶²ã§åŠçããã®ã¡ãæ¬çºæç©è³ª
ãæäœãããããããæ¬çºæç©è³ªã®æäœè¡çãšã
ãŠè©Šæã«äŸããã æ¹ æ³ ã¢ã¯ãªã«è£œã®ãã€ã¯ãã¿ã€ãã¬ãŒã·ãšã³ãã¬ãŒ
ãïŒïŒ¶âã¿ã€ãïŒã«ïŒïŒ æ£åžžå®¶å è¡æž ãå«æãã
ãªã³é žç·©è¡ççé£å¡©æ¶²ïŒ0.15MãPH7.2ïŒ25ÎŒã
æ·»å ããè¡æž ãäºç³»åãã€2nååžéããã次ã«äž
æ¹ã®ç³»åã«ã¯ïŒïŒ æ£åžžå®¶å è¡æž ãå«æãããªã³é ž
ç·©è¡ççé£å¡©æ¶²ïŒ0.15MãPH7.2ïŒ25ÎŒããä»æ¹
ã®ç³»åã«ã¯æ¬çºæç©è³ª25ÎŒãæ·»å ãã37âã§30
åéã€ã³ããŠããŒãããããã®åŸæäœè¡çãæ·»å
ãã宀枩ã§ïŒæéæŸçœ®ããåéã®æç¡ã確èªã
ããç·©è¡æ¶²åŽã®åé䟡ãïŒç®¡ïŒïŒååžéïŒä»¥äžã
瀺ããæ¬çºæç©è³ªæ·»å ã«ããåéæå¶ãïŒç®¡ä»¥äž
確èªãããå Žåã«éœæ§ãšå€å®ããåéãèªããæ
çµåžéåæ°ãæäœäŸ¡ãšããã çµ æ äœè£œããæåæäœè¡çã«ããåéåå¿ã®æ床ã¯
å®éšäŸïŒã«ãããå¯å€©ã²ã«å åå¿ã®ããã«æ¯ã¹
100ã200å以äžã§ãã€ãããŸãåéæäœã®ç¹ç°æ§
ã¯æ¬æåããã³æ£åžžããèäžæž ã«ããåéæå¶ã®
æç¡ããæçã«ç¢ºèªããããšãã§ããã å®éšäŸ ïŒ è©Š æ ïŒ å®éšäŸïŒè©Šæã®é èšèŒã®æäœè¡ç ïŒ äžèšïœãïœã®åçš®é¡ã®å¯Ÿè±¡æ€äœ ïœ æ¥æ§ãŠã€ã«ã¹æ§èççäŸãšããŠïŒ¡åã§ãã
14äŸã®æ£è ã®è¡æž ïœ æ¥æ§ãŠã€ã«ã¹æ§èççäŸãšããŠïŒ¢åã§ãã
12äŸã®æ£è ã®è¡æž ïœ æ¥æ§ãŠã€ã«ã¹æ§èççäŸãšããŠééå
ã§ãã15äŸã®æ£è ã®è¡æž ïœ æ£åžžäŸè¡è 129äŸã®è¡æž æ¹ æ³ å身赀è¡çåéåå¿æ³ãå©çšããŠãå察象æ€äœ
ã«ãããæ€åºé »åºŠã確èªãããããªãã¡åè¡æž ã«
ãããŠ2nååžéãäºåäœè£œããäžæ¹ã®ç³»åã«æ¬çº
æç©è³ªïŒ50ååžé液ïŒãæ·»å ãã37âã§30åéã€
ã³ããŠããŒãããã®ã¡ãæäœè¡çãæ·»å ããïŒã
ïŒæéåŸã«åéåã芳å¯ãããïŒç®¡ïŒïŒååžéïŒ
以äžã®åé䟡ã瀺ããæ¬çºæç©è³ªã«ããæå¶ãïŒ
管以äžç¢ºèªãããå Žåã«ãåœè©²è¡æž ã«ã€ããŠæäœ
éœæ§ãšå€å®ããã çµ æ çµæãè¡šïŒã«ç€ºãã
ã«é¢ãããããã«è©³ããã¯ãééåèçé¢é£
æåããã³åœè©²æåã®çµåäœäžŠã³ã«ããããäž»èŠ
ãªæ§ææåãšããŠå«æããééåèç蚺æè¬
ã«é¢ããã ãŠã€ã«ã¹èçã«ã€ããŠã¯åŸæ¥ããåããã³ïŒ¢
åã®ååšãç¥ãããŠããããã§ã«é¢é£æåæäœç³»
ãæããã«ããããããå©çšããå ç«è¡æž åŠçãª
蚺æãå¯èœãšãªããããã«ã¯ã¯ãã³ã®éçºãå°å ¥
ã«ãŸã§è³ã€ãŠããã ããããªãããããã«äŒŽã€ãŠééåèçã
ããªãã¡ãåŸæ¥ããç¥ãããŠããåèçããã³
åèçã®ãããã«ãå±ããªããŠã€ã«ã¹èçã®å
åšãç¥ãããããã«ãªããããããã®çºçé »åºŠã
äºæ³ä»¥äžã«é«ãããšãæãããšãªã€ãŠæ¥ããäŸã
ã°ã茞è¡åŸèçã®80ã90ïŒ ãããã¯ããã«ãã以
äžã®ãã®ãééåèçã§ãããæ£çºçã«çºç
ããæ¥æ§èçã«ã€ããŠãçŽ50ïŒ ã¯ééåèç
ã§ããããšãå ±åãããã«è³ã€ãŠããããŸãæ£åžž
äŸè¡è ã®äžã«ããééåèçãŠã€ã«ã¹ã®ä¿æ
è ãããªãã®æ°ååšããããšãæãããšãªã€ãŠæ¥
ãã以äžã«èšèŒããæç®ã¯ééåèçã«é¢ã
ãäžè¿°ã®ç¶æ³ãå ±åãããã®ã§ãããåèã®ãã
ã«åæããã (1) PrinceãA.M.et al.ïŒLongâincubation
postâtransfusion hepatitis without
serological evidence of exposure to
hepatitisâ virus.Lancet.ïŒ241â246ã
1974. (2) AlterãH.J.et al.ïŒClinical and
serological analysis of transfusionâ
associated hepatitis.Lancet.ïŒ838â841ã
1975. (3) FeinstonsãS.M.et al.ïŒTransfusionâ
associated hepatitis not due to viral
hepatitis type  or B.N.Engl.J.Med.292ïŒ
767â770ã1975. (4) MeyersãJ.D.et al.ïŒParenterally
transmitted nonâãnonâ hepatitis.
Ann.Intern.Med.87ïŒ57â59ã1977. (5) VillarejosãV.M.et al.ïŒEvidence for
viral hepatitis other than type  or type
 among persons in Costa Rica.N.Engl.J.
Med.293ïŒ1350â1352.1975. (6) DienstagãJ.L.et al.ïŒEtiology of
sporadic hepatitis  surface antigenâ
negative heâpatitis.Ann.Intern.Med.87ïŒïŒ
âïŒã1977. ããŠãããã§ééåèçãšã¯ïŒ¡åèçãŠã€
ã«ã¹ãåèçãŠã€ã«ã¹ããµã€ãã¡ã¬ããŠã€ã«
ã¹ããšãã¹ã¿ã€ã³ããŒãŠã€ã«ã¹ãªã©åŸæ¥ç¥ããã
ãŠã€ã«ã¹ä»¥å€ã®ãŠã€ã«ã¹ãç åäœãšããŠé¢äžãã
ããšã«ããçºçãããšèããããèçã§ãã€ãŠã
HAæäœãHBsæäœãHBcæäœãHBeæäœã«ã€
ããŠææã®äžæãèªããããªããã®ãèšããåŸã€
ãŠãééåèçæ£è ãšã¯ãèçãŠã€ã«ã¹ã«èµ·
å ããèçæ£è ã§ãã€ãŠïŒ¡åèç蚺æããã³ïŒ¢å
èç蚺æã«ãããŠé°æ§ã瀺ããåèçããã
åèçãããé€å€ãããæ£è ã§ãããšå®çŸ©ãã
ããäžè¬ã«ééåèçã§ã¯ãåèçã«æ¯èŒ
ãããšèŒžè¡ããçºçãŸã§ã®å¹³åæœäŒæãçãããŸ
ãGPTã®æ倧å€ãäœããšããåŸåãããããã
ããã®åé¢ãæç¶æ§ããããäŸãã°GPTç°åžžã¯
æ ¢æ§åããŠããªãã®é·æéã«åã¶ãšããç¹åŸŽãã
ãããããããããã«ãããééåèçã¯èŒž
è¡åŸèçã®å€§éšåãå ããŠããããã€ééå
èçãŠã€ã«ã¹ãåå ãšãªãèçŸæ£ã¯è硬å€ãèç
ãªã©åºç¯å²ã«åãã§ãããé©åãªã察å¿çãæ©æ¥
ã«éçºãããããšãæãŸããŠããã®ã§ããããã
ãã«ãééåèçã«ã€ããŠã¯ãæªã ãã®ãŠã€
ã«ã¹æ¬æ ãããã¯ããã«é¢é£ããæåæäœç³»ã確
ç«ãããŠããããåŸã€ãŠé©åãªã蚺æããã³ã¯ã¯
ãã³ã®è£œé ããªãããŠããªãã®ãçŸç¶ã§ããã ééåèçé¢é£æåã«é¢ããå è¡æè¡ãšã
ãŠã¯ç¹éæ55â122156å ¬å ±ã«èšèŒãããçºæãã
ããHCæåãšåœåãããç©è³ªã®æäŸãé瀺ãã
ãŠããããããããã®HCæåã¯ãã€ã±ãåè
çå埩ææ£è ã®è¡æŒ¿ãŸãã¯è¡æž ãšã®éã«ãããŠæ
åæäœåå¿ãçããç¹ã«ç¹åŸŽããããééå
èçã«ãããåºãäžè¬åããåå¿æ§ã瀺ãã«è³ã€
ãŠããªãããŸãåœè©²HCæåãåé¢ç²Ÿè£œãããã
ã®åºçºç©è³ªãšããŠã¯HBsæåé°æ§è¡æ¶²ã茞è¡ã
ãã®ã¡ã«èçãçºçããGPTã®äžæãäºå³°æ§ãŸ
ãã¯ãã以äžã®å€å³°æ§ã瀺ãããã€æœäŒæã®æ¯èŒ
çé·ãæ£è 矀ã®æ¥æ§æè¡æŒ¿ãŸãã¯è¡æž ãéžæããŠ
䜿çšããå¿ èŠããããåºçºç©è³ªãšããŠã®éå®æ¡ä»¶
ãããªãå€ããšããæ¬ ç¹ãããã ãããå®æ ã«ãããã¿ãæ¬çºæè ã¯ééå
èçã«ã€ããŠäžè¬çã§ããããã€ééåèç
ã«ç¹ç°çã§ããé¢é£æåãç©è³ªãšããŠåé¢ããã
ãšãè©Šã¿ããã®çµæãééåèçåæ€èãã
ã®åé¢ç²Ÿè£œã«ããææã®ç©è³ªãååŸããããšã«æ
åããæ¬çºæãå®æããã«è³ã€ãã æ¬çºæç©è³ªã¯ééåèçåæ€èããåé¢ç²Ÿ
補ããããã®çååŠçæ§ç¶ã¯ä»¥äžã®ããšãã§ã
ããååéã¯ã²ã«éæ³ã«ããæ±ãããš150äžä»¥
äžã§ãããæ²éå®æ°ïŒ10-13ïŒã¯Beckmann
Model ã§æž¬å®ãããš51.5Sã瀺ããå¡©åã»ã·ãŠ
ã ãŸãã¯èåã«ãªãŠã 溶液äžã®æµ®äžå¯åºŠïŒïœïŒ
cm3ïŒã¯ã¢ããã®å±æèšã«ãã€ãŠæ±ãããš1.15ã
1.25ã§ãããç²åçŽåŸïŒïœïœïŒã¯é»åé¡åŸ®é¡èŠ³å¯
ã«ãããš26ã37ïŒå¹³å31.5ïŒã§ãããé»æ°ç移å
床ã¯å ç«é»æ°æ³³åæ³ã«ããæ±ãããšÎ±2âα1ã°ãã
ãªã³ã®é åã§ããã 以äžããæãããªããšããæ¬çºæç©è³ªã¯åºçºç©
質䞊ã³ã«çååŠçæ§ç¶ã«ãããŠç¹éæ55â122156
å ¬å ±ã«èšèŒã®HCæåãšã¯ç°ãªãç©è³ªã§ããããš
ãç¥ãããã ãŸãæ¬çºæç©è³ªã¯åŸèšå®éšäŸã«ç€ºãããããšã
ééåèçå埩ææ£è è¡æž ããã³é »å茞è¡æŽ
ã®ããæ£è ã®è¡æž ãšã®éã«å¯å€©ã²ã«å ã®æ²éåå¿
ã瀺ãããŸãæ¬çºæç©è³ªãæäœããçŸèµ€è¡çã¯é
éåèçæ£è ã®å埩æè¡æž ãšã®éã«ç¹ç°çã«
ãããé«æ床ã§å身赀è¡çåéåå¿ã瀺ãããã®
åé¢ãæ¬çºæç©è³ªã¯HAæäœãHBsæäœãHBeæ
äœãHBcæäœãÎŽæäœãHCæäœãEBæäœã
Araiæäœãæäœãæ£åžžããèäžæž æäœããã
ã³åçš®ã®æ£åžžããè¡æŒ¿æäœã®ããããšãåå¿ã瀺
ããªãã€ããåŸã€ãŠãæ¬çºæç©è³ªã¯ééåè
çã«ã€ããŠäžè¬çã§ããããã€ééåèçã«
ç¹ç°çãªé¢é£æåãšããŠæçšãªç©è³ªã§ããããšã
å€æãããäŸãã°å®éšäŸïŒã«ç€ºãããšãéé
åèççç¶ã®çµé蚺æã«ãããŠæ£ç¢ºãªæ å ±ãæäŸ
ããäžã§æçšã§ããã ãŸãæ¬çºæç©è³ªãé©åœãªãã¢ãžãŠãã³ããäŸã
ã°ããã€ã³ãå®å šã¢ãžãŠãã³ããšå ±ã«å®¶å ã«é »å
æäžããããšã«ããæ¬çºæç©è³ªã«å¯Ÿããå ç«æäœ
ãç£çããããããšãå¯èœã§ãããåŸã€ãŠãæ¬çº
æç©è³ªã¯ééåèçã¯ã¯ãã³ã®è£œé ã®çŽ æãš
ããŠããã®æçšæ§ãæåŸ ããããã®ã§ããã 次ã«æ¬çºæç©è³ªã¯ééåèçåæ€èãåºçº
ç©è³ªãšããŠéåžžã®ã¿ã³ãã¯åå粟補æ³ãäŸãã°å¯
床åŸé é å¿åé¢æ³ãå¡©ææ³ãé»æ°æ³³åæ³ãã²ã«
éæ³ãã¢ãã€ããã€ãŒã¯ãããã°ã©ãã€ãŒæ³ãç
é»ç¹ååæ³ãéå€éæ³ãã³ãŒã³ã®ååæ³ãé©å®
çµåãããŠååŸããããšãã§ããã奜ãŸããå®æœ
äŸã®æŠèŠããã€ãŠèª¬æããã°ããŸãåæ€èãã¢ãž
ããŒãäžæž ã«ã€ããŠäŸãã°ã»ãã¢ã¯ãªã«ïŒ³â200
ãçšããŠã«ã©ã ã¯ãããã°ã©ãã€ãŒååãè¡ãã
åŸãããæåéœæ§ãã©ã¯ã·ãšã³ãéå€éããŠå
å§æ¿çž®ããæåŸã«è¶ é å¿åé¢ãšéæãç¹°è¿ããã
ãã§è¶ é å¿åé¢ã«ã¯èç³æ¿åºŠåŸé é å¿ããã³å¡©å
ã»ã·ãŠã å¯åºŠåŸé é å¿ãçµåãããŠäžåãªããæ°
åè¡ãã®ã奜ãŸãããåŸããã粟補ç©ã¯å¯å€©ã²ã«
å åå¿ã«ããééåèçå埩æè¡æž ãšã®éã«
æçãªäžæ¬ã®æ²éç·ã瀺ãã粟補åã®åæ€èãã¢
ãžããŒãäžæž ã«ãããæ²éç·ãšå®å šã«èåããã
ãšã確èªããããã€ãŸããæ¬çºæç©è³ªã¯ãæ¬çºæ
ã«ä¿ãåé¢ç²Ÿè£œæ³ã«ãã€ãŠå ç«åŠçæ§ç¶ãæãã
ãšãªãåé¢ãããããšã確èªãããã®ã§ããã 次ã«æ¬çºæç©è³ªãäž»èŠãªæ§ææåãšããŠå«æã
ã蚺æè¬ã¯æ¡çšããå ç«åŠçæ€åºæ¹æ³ã«å¿ããŠé©
å®èª¿è£œããã°ãããäŸãã°æ€åºæ¹æ³ãšããŠãªã¯ã¿
ãããŒæ³ïŒMOïŒãå ç«é»æ°æ³³åæ³ïŒIESãIEPïŒã
è£äœçµååå¿æ³ïŒCFïŒãå ç«ç²çè¡çåéåå¿æ³
ïŒIAHAïŒãäžå å¹³æ¿å ç«æ¡æ£æ³ïŒSRIDïŒãå©çš
ããå Žåã«ã¯æ¬çºæç©è³ªããã®ãŸãŸäœ¿çšããŠé©åœ
ãªåœ¢æ ã«èª¿è£œããã°ãããäžäŸãšããŠäžå å¹³æ¿å
ç«æ¡æ£æ³ãå©çšããå Žåã瀺ãã°ãæ¯æäœãšããŠ
å¯å€©ãã¢ã¬ããŒã¹ããã³ãã³ãããªã¢ã¯ãªã«ã¢ã
ãã²ã«çã®äžããé©åœãªãã®ãéžã³ããããç·©è¡
液ã«å ç±æº¶è§£ãã次ã«æ¬çºæç©è³ªãæ·»å æ··åãã
åŸããã溶液ãã¬ã©ã¹æ¿äžãããã¯ãã©ã¹ããã¯
容åšå ã«æµãå·åŽåºåããåºåããã²ã«å¹³æ¿ã«è¢«
æ€è¡æž æ³šå ¥çšã®åããããã°ããã ãããã«ãæ€åºæ¹æ³ãšããŠè¡çåéåå¿æ³
ïŒPHAïŒãæŸå°æ§å ç«æž¬å®æ³ïŒRIAïŒãé µçŽ æäœæ³
ïŒELISAïŒçãå©çšããå Žåã«ã¯æ¬çºæç©è³ªã«é©
åœãªãå å·¥åŠçãæœãå¿ èŠããããããªãã¡è¡ç
åéåå¿æ³ïŒPHAïŒãå©çšããå Žåã«ã¯æ¬çºæ
ç©è³ªã埮å°ç²åã«çµåãããå¿ èŠãããã埮å°ç²
åãšããŠã¯åºä¹³é¡ããã³é³¥é¡ã®è¡çã奜ãŸãã
ãããã®ä»ãããªã¹ãã¬ã³ã©ããã¯ã¹ãããªãšã¹
ãã«ã©ããã¯ã¹ãå¡©åããã«ããã³ããã€ããã¬
ã©ã¹ããŒãºçã®çŽïŒã10ÎŒã®ç²åã䜿çšããããš
ãã§ãããæ¬çºæç©è³ªãšåŸ®å°ç²åãçµåãããã«
ã¯ãäŸãã°ã°ã«ã¿ãŒã«ã¢ã«ãããããã«ã ã¢ã«ã
ãããã¿ã³ãã³é žããã¹ãžã¢ãŸãã€ãºãã³ããž
ã³ãå¡©åã¯ãã ãã«ã«ããžã€ãããªã©ã䜿çšãã
ã°ããã æŸå°æ§å ç«æž¬å®æ³ïŒRIAïŒãå©çšããå Žåã«ã¯
æ¬çºæç©è³ªãã¢ã€ãœããŒãã§ã©ãã«åããå¿ èŠã
ãããã¢ã€ãœããŒããšããŠã¯ 125Iã 131Iã䜿çš
ããããšãã§ããã¯ãã©ãã³ïŒŽæ³ã«ããçµåãã
ãã°ããã é µçŽ æäœæ³ïŒELISAïŒãå©çšããå Žåã«ã¯ã
æ¬çºæç©è³ªãé µçŽ ãšçµåãããå¿ èŠããããé µçŽ
ãšããŠã¯ãäŸãã°ã°ã«ã³ãŒã¹ãªãã·ããŒãŒãã¢ã«
ã«ãªãã¹ãã¢ã¿ãŒãŒããã«ãªãã·ããŒãŒãããŒã¿
ãŒã¬ã©ã¯ãã·ããŒãŒçã䜿çšããããšãã§ããã
çµåå€ãšããŠã¯ã°ã«ã¿ãŒã«ã¢ã«ãããã䜿çšãã
ã°ããã æ¬çºæ蚺æè¬ã¯ééåèçã®èšºæã®ããã«
䜿çšããããããã®ã»ãã«ééåèçæäœã®
è©Šéšçãªæ€åºçšè©Šè¬ãããã¯å®éçšè©Šè¬ãšããŠã
䜿çšããããšãã§ããããšã¯ãã¡ããã§ãããåŸ
ã€ãŠãæ¬çºæã®èšºæè¬ã¯ãã®çšèªãç矩ã«è§£éã
ããã®ã«éå®ããããã®ã§ã¯ãªãã æ¬çºæç©è³ªããã³èšºæè¬ã®æçšæ§ã以äžã«èšèŒ
ããå®éšäŸããã€ãŠèª¬æããã å®éšäŸ ïŒ è©Š æ  æ¬çºæç©è³ª  ééåèçå埩ææ£è ã®è¡æž ãã®äž  ééåèçå埩ææ£è ã®è¡æž ãã®äº  é »å茞è¡æŽã®ããæ£è ã®è¡æž  æ£åžžããè¡æž  æ£åžžããèãã¢ãžããŒãäžæž æ¹ æ³ ã¢ã¬ããŒã¹ïŒ¡â45ïŒåäºååŠïŒ0.8ïŒ ïŒïœïŒïœïŒã
EDTAã»3Na0.02Mãå¡©åãããªãŠã 0.1Mã
NaN30.1ïŒ ãããªã¹å¡©é žç·©è¡æ¶²ïŒ0.01MãPH7.5ïŒ
ã«æº¶è§£ããåã1.5mmã®å¯å€©ã²ã«å¹³æ¿ãäœè£œãã
è©Šæã«ã€ããŠãã€ã¯ããªã¯ã¿ãããŒæ³ã«ããæ€åº
ãã¹ãããããªã€ãã çµ æ çµæãå³ïŒã«ç€ºããå³ïŒããæãããªããšãæ¬
çºæç©è³ªã¯ééåèçå埩ææ£è ã®è¡æž ãã
ã³é »å茞è¡æŽã®ããæ£è ã®è¡æž ãšæ²éç·ãçæ
ãããããã¯å®å šã«èåããŠããããšã確èªãã
ããåŸã€ãŠããããã¯å ç«åŠçã«åäžã®ç¹ç°æ§ã
æããæåæäœç³»ã§ããããšãå€æããããŸãã
ã®æåæäœç³»ã¯æ£åžžããè¡æž ããã³æ£åžžããèã
ã¢ãžããŒãäžæž ãšã®äº€å·®åå¿ããŸã€ãã瀺ããŠã
ãªãã å®éšäŸ ïŒ è©Š æ çŸèµ€è¡çãã°ã«ã¿ãŒã«ã¢ã«ããã溶液ã§åºå®
ããã¿ã³ãã³é žæº¶æ¶²ã§åŠçããã®ã¡ãæ¬çºæç©è³ª
ãæäœãããããããæ¬çºæç©è³ªã®æäœè¡çãšã
ãŠè©Šæã«äŸããã æ¹ æ³ ã¢ã¯ãªã«è£œã®ãã€ã¯ãã¿ã€ãã¬ãŒã·ãšã³ãã¬ãŒ
ãïŒïŒ¶âã¿ã€ãïŒã«ïŒïŒ æ£åžžå®¶å è¡æž ãå«æãã
ãªã³é žç·©è¡ççé£å¡©æ¶²ïŒ0.15MãPH7.2ïŒ25ÎŒã
æ·»å ããè¡æž ãäºç³»åãã€2nååžéããã次ã«äž
æ¹ã®ç³»åã«ã¯ïŒïŒ æ£åžžå®¶å è¡æž ãå«æãããªã³é ž
ç·©è¡ççé£å¡©æ¶²ïŒ0.15MãPH7.2ïŒ25ÎŒããä»æ¹
ã®ç³»åã«ã¯æ¬çºæç©è³ª25ÎŒãæ·»å ãã37âã§30
åéã€ã³ããŠããŒãããããã®åŸæäœè¡çãæ·»å
ãã宀枩ã§ïŒæéæŸçœ®ããåéã®æç¡ã確èªã
ããç·©è¡æ¶²åŽã®åé䟡ãïŒç®¡ïŒïŒååžéïŒä»¥äžã
瀺ããæ¬çºæç©è³ªæ·»å ã«ããåéæå¶ãïŒç®¡ä»¥äž
確èªãããå Žåã«éœæ§ãšå€å®ããåéãèªããæ
çµåžéåæ°ãæäœäŸ¡ãšããã çµ æ äœè£œããæåæäœè¡çã«ããåéåå¿ã®æ床ã¯
å®éšäŸïŒã«ãããå¯å€©ã²ã«å åå¿ã®ããã«æ¯ã¹
100ã200å以äžã§ãã€ãããŸãåéæäœã®ç¹ç°æ§
ã¯æ¬æåããã³æ£åžžããèäžæž ã«ããåéæå¶ã®
æç¡ããæçã«ç¢ºèªããããšãã§ããã å®éšäŸ ïŒ è©Š æ ïŒ å®éšäŸïŒè©Šæã®é èšèŒã®æäœè¡ç ïŒ äžèšïœãïœã®åçš®é¡ã®å¯Ÿè±¡æ€äœ ïœ æ¥æ§ãŠã€ã«ã¹æ§èççäŸãšããŠïŒ¡åã§ãã
14äŸã®æ£è ã®è¡æž ïœ æ¥æ§ãŠã€ã«ã¹æ§èççäŸãšããŠïŒ¢åã§ãã
12äŸã®æ£è ã®è¡æž ïœ æ¥æ§ãŠã€ã«ã¹æ§èççäŸãšããŠééå
ã§ãã15äŸã®æ£è ã®è¡æž ïœ æ£åžžäŸè¡è 129äŸã®è¡æž æ¹ æ³ å身赀è¡çåéåå¿æ³ãå©çšããŠãå察象æ€äœ
ã«ãããæ€åºé »åºŠã確èªãããããªãã¡åè¡æž ã«
ãããŠ2nååžéãäºåäœè£œããäžæ¹ã®ç³»åã«æ¬çº
æç©è³ªïŒ50ååžé液ïŒãæ·»å ãã37âã§30åéã€
ã³ããŠããŒãããã®ã¡ãæäœè¡çãæ·»å ããïŒã
ïŒæéåŸã«åéåã芳å¯ãããïŒç®¡ïŒïŒååžéïŒ
以äžã®åé䟡ã瀺ããæ¬çºæç©è³ªã«ããæå¶ãïŒ
管以äžç¢ºèªãããå Žåã«ãåœè©²è¡æž ã«ã€ããŠæäœ
éœæ§ãšå€å®ããã çµ æ çµæãè¡šïŒã«ç€ºãã
ãè¡šã
è¡šïŒãã以äžã®ç¹ãå€æããã
ïŒ ééåèçäŸã«ãããŠã¯éœæ§äŸã¯73.3ïŒ
ãšããé«çã§ãããæ£åžžäŸè¡è ãåèçäŸã
åèçäŸã®ããããšãææãªå·®ã瀺ããã ïŒ ïŒ¡åèçäŸããã³ïŒ¢åèçäŸã«ãããŠã¯éœæ§
äŸã¯ãããã14.3ïŒ ã16.7ïŒ ã§ããããæ£åžžäŸ
è¡è ã®éœæ§äŸãšã®éã«ã¯ææãªå·®ãèªããããª
ãã ïŒ ééåèçæäœã¯æ£åžžäŸè¡è ã®çŽïŒïŒ ã«
ãã®ååšãèªããããã ïŒ å¹³ååé䟡ã«ãããŠããæ£åžžäŸè¡è è¡æž ã
åèçäŸè¡æž ãåèçäŸè¡æž ã®éã«ã¯ææãª
å·®ãèªããããªãããééåèçäŸè¡æž ã¯
æ£åžžäŸè¡è è¡æž ã«æ¯èŒããŠææïŒïœïŒ0.001ïŒ
ã«é«ãå€ã瀺ããã 以äžïŒä¹è³ïŒãããæ¬çºæç©è³ªãééåè
çæäœã«ã€ããŠäžè¬çã§ããããã€ééåè
çæäœã«ç¹ç°çãªæåã§ããããšãç¥ãããã å®éšäŸ ïŒ è©Š æ ééåèçæ£è ïŒäŸã®çµéè¡æž æ¹ æ³ çµéè¡æž ã«ã€ãééåèçæäœããã³
GPTã枬å®ãããééåèçæäœã¯æ¬çºæ
ç©è³ªãçšããŠå身赀è¡çåéåå¿æ³ã«ãã枬å®ã
ãã çµ æ çµæãå³ïŒä¹è³å³ïŒã«ç€ºããåå³ããæãããª
ããšããééåèçæäœã¯çºççŽåŸïŒGPT
ã®æ¥µæïŒã«ãããŠã¯è¡æž äžã«æ€åºãããªãããŸã
ã¯ããå ãã§ããããèæ©èœã®æ£åžžåïŒGPTã®
æžå°ïŒã«äŒŽãè¡æž äžã«åºçŸãããã®æäœäŸ¡ã¯ïŒã
ïŒå¹Žä»¥äžç¶æãããã®ã確èªããããããã®ããš
ãééåèçæäœã¯ééåèçã®èšºæã
ãã³äºåŸã®çµé芳å¯ã«æçšãªè¡äžããŒã«ãŒãšãªã
ã®ã§ãåœè©²æäœã«ã€ããŠäžè¬çã§ããããã€åœè©²
æäœã«ç¹ç°çã§ããæ¬çºæç©è³ªã¯ééåèç
ã«ã€ããŠã®æ£ç¢ºãªèšºæè¬ãæäŸãããã®ã§ããã
ãšãç¥ãããã 以äžã«èšèŒããå®æœäŸããã€ãŠæ¬çºæãããã«
詳现ã«èª¬æãã å®æœäŸ ïŒ ééåèçæ£è ã®åæ€èçŽïŒïœã现åãã
ããªã¹å¡©é žç·©è¡ççé£å¡©æ¶²ïŒ0.01MãPH7.5ïŒ20
mlãå ãããã¢ãžãã€ãºããã次ã«10000rpmã§
20åéé å¿ããŠããã®äžæž ããšããåé¢ç²Ÿè£œåã®
èãã¢ãžããŒãäžæž ãšããã ãããããããªã¹å¡©é žç·©è¡ççé£å¡©æ¶²
ïŒ0.01MãPH7.5ïŒã§å¹³è¡¡åããã»ãã¢ã¯ãªã«ïŒ³â
200ïŒãã¢ã«ãã·ã¢è£œïŒã®å å¡«ã«ã©ã ïŒ2.6Ã90cmïŒ
ã«èãã¢ãžããŒãäžæž 10mlãæ·»å ããããªã¹å¡©é ž
ç·©è¡ççé£å¡©æ¶²ïŒ0.01MãPH7.5ïŒã§æº¶åºãã
280nïœã®çŽ«å€éšåžåã§é£ç¶ã¢ãã¿ãŒããªããã
æå掻æ§ãæãã第äžããŒã¯ã®çžåœååãããŒã«
ããããªããæå掻æ§ã¯å¯å€©ã²ã«å åå¿ã«ããæ€
玢ãããããŒã«ããååã¯éå€éæ³ïŒã¢ãã³ã³
補PMâ10ïŒã«ãã€ãŠå å§æ¿çž®ããã 次ã«åŸãããæ¿çž®æ¶²ã«ã€ããŠãæ¯æäœãšããŠã»
ãã¢ã¯ãªã«ïŒ³â200ïŒãã¢ã«ãã·ã¢è£œïŒã®ä»£ããã«
ã»ãã¢ã¯ãªã«ïŒ³â300ïŒãã¢ã«ãã·ã¢è£œïŒã䜿çšã
ãŠäžèšèšèŒã«ããããšåæ§ã«æº¶åºæäœããããª
ããåã³éå€éæ³ã«ããå å§æ¿çž®ããã 次ã«åŸãããæ¿çž®æ¶²ïŒmlã«ã€ããŠèç³æ¿åºŠåŸé
é å¿åé¢ïŒ24000rpmã16æéïŒããããªã€ãã
æ¿åºŠåŸé ã¯ïŒã60ïŒ ïŒïœïŒïœïŒã®ç¯å²ã«ãããŠã
ããªããïŒïŒ ã15ïŒ ã25ïŒ ã35ïŒ ã§ã¯å10mlã«ã
45ïŒ ã60ïŒ ã§ã¯åïŒmlã«ãªãããã«äœè£œããæ¿çž®
液ãæäžéšã«æ·»å ãããåŠçåŸããŠãŒãåºãã
2.5mlïŒtubeã®å²åã§ååããæå掻æ§ãæãã
èç³æ¿åºŠ25ã40ïŒ çžåœååãããŒã«ãããããŒã«
ããååã«ã€ããŠããªã¹å¡©é žç·©è¡ççé£å¡©æ¶²
ïŒ0.01MãPH7.5ïŒã§éæããããªããéå€éæ³
ïŒã¢ãã³ã³è£œPMâ10ïŒã«ããå å§æ¿çž®ããã 次ã«åŸãããæ¿çž®æ¶²ã«ã€ããŠå¡©åã»ã·ãŠã 平衡
å¯åºŠåŸé é å¿åé¢ïŒ40000rpmã20æéïŒããã
ãªã€ãã1.00ã1.50ïœïŒcm3ã®å¯åºŠåŸé ç¯å²ã«ãã
ãŠå4.5mlãäœè£œããæ¿çž®æ¶²ãæäžéšã«æ·»å ããã
åŠçåŸãããŠãŒãäžå±€ããã0.2mlïŒtubeã®å²å
ã§ååããæå掻æ§ãæããå¡©åã»ã·ãŠã å¯åºŠ
1.15ã1.25ïœïŒcm3çžåœååãããŒã«ããããªãå
ååã®æ¯éã¯ã¢ããã®å±æèšã§æž¬å®ãããããŒã«
ããååã«ã€ããŠã®ããªã¹å¡©é žç·©è¡ççé£å¡©æ¶²
ïŒ0.01MãPH7.5ïŒã§éæããã ããã«åŸããã溶液ã«å«ãŸããç©è³ªã®çååŠç
æ§ç¶ã¯äžèšã®ããšãã§ãããå®éšäŸïŒãïŒãïŒã
ïŒã®åå®éšã«ãããæ¬çºæç©è³ªãšããŠäœ¿çšããã ååé 150äžä»¥äžïŒã²ã«éæ³ïŒ æ²éå®æ°ïŒ10-13ïŒ 51.5SïŒè¶ é å¿åææ³ïŒ æµ®äžå¯åºŠïŒïœïŒcm3ïŒ 1.15ã1.25ïŒå¡©åã»ã·ãŠã
äžããã³èåã«ãªãŠã äžïŒ ç²åçŽåŸïŒïœïœïŒ 26ã37 é»æ°ç移å床
α2âα1ã°ãããªã³é åïŒã¢ã¬ããŒã¹ã²ã«äžïŒ ãŸããæ¬çºæç©è³ªã«å¯ŸããæäœïŒééåè
çæ£è ã®å埩æè¡æž ç±æ¥ïŒãçšæãããããšæ¬çº
æç©è³ªãšãè©Šéšç®¡å ã§æ··åãã37âã§60åéã€ã³
ããŠããŒãããã€ã¥ããŠïŒâã§äžæŒå€é眮ãã
10000rpmã§20åéé å¿åé¢ããããã®çµæãæ¬
çºæç©è³ªã¯æåæäœè€åç©ã®æ²æž£ãšããŠååã
ãããããé»é¡èŠ³å¯ãããšãçŽåŸçŽ26ã37nïœã®
ç圢ç²åãçžäºã«åéããŠããã®ãã¿ãããã å®æœäŸ ïŒ å®æœäŸïŒã§åŸããã溶液ã«ããã€ã³ãå®å šã¢ãž
ãŠãã³ããïŒïŒïŒã®æ¯ã«å ããŠä¹³åãããä¹³å液
0.5mlããŠãµã®ã®èéšç®äžãç®å ããã³è¶³è¹ éšã«
åå²æ³šå°ããŠå ç«ãããïŒé±éåŸã«åéã®ä¹³å液
ãåæ§ã«ããŠè¿œå å ç«ããããã«ååã®å ç«ãã
ïŒã«æåŸã«åéã®ä¹³å液ãå床远å å ç«ãããæ
åŸã®å ç«ããïŒé±éåŸããæ°åã«ããã€ãŠæ¡è¡
ããè¡æž ãåé¢ããããã®è¡æž ã«åéã®æ£åžžãã
èè¡æž ãå ãã37âã§ïŒæéãããã«ïŒâã§ïŒå€
æŸçœ®ãããããã10000rpmã§10åéé å¿åé¢ãã
äžæŸæ¶²ãæ¡åãããåŸãããæè¡æž äžã®æäœãç¡«
é žã¢ã³ã¢ããŠã ã«ããå¡©æããã³DEAEã»ã«ããŒ
ãºã«ããã«ã©ã ã¯ãããã°ã©ãã€ãŒã«ãã粟補
ããã€ãã§PH9.0ã0.1Mã®ãã«ãã¿ãŒã«ç·©è¡æ¶²ã«
溶解ããèçœè³ªæ¿åºŠã10mgïŒmlã«èª¿è£œããããã
ãããã ã·ã¢ã³æŽ»æ§åã»ãã¢ããŒãº4Bã²ã«ã«å
éå ããïŒâã§24æéåå¿ããããã€ãã§æªåå¿
ã®èçœè³ªãPH7.5ã0.05Mã®ãªã³é žç·©è¡ççé£å¡©
液ã§æŽæµé€å»ããåŸããããçŽåŸ1.5cmãé·ã20
cmã®ã«ã©ã ã«å å¡«ããããã®ã«ã©ã ã«å®æœäŸïŒã§
åŸããã溶液ãæ·»å ãããåèšãªã³é žç·©è¡ççé£
塩液ãçšããŠæªåå¿ç©ãæŽæµé€å»ããåŸã解é¢å€
ãã«ã©ã ã«å ãã溶åºãããããæ¡åãã溶åºæ¶²
ãèžçæ°Žã§éæããŠè§£é¢å€ãé€å»ããã€ãã§ã¢ã
ã³ã³ãã€ã€ãããŒXMâ50ã«ãã€ãŠæ¿çž®ãããã
ãã«åŸããã溶液ã¯å®æœäŸïŒãïŒãïŒã®PHAæ³ã
RIAæ³ãEIAæ³ãå©çšãã蚺æè¬ã補é ãããã
ã®ééåèçé¢é£æåã«äœ¿çšãããã å®æœäŸ ïŒ ãããžè¡æ¶²ãé å¿ç®¡ã«ãšããççé£å¡©æ¶²ãçšã
ãŠ2000rpmã§10åéã®é å¿åé¢ãïŒåç¹°è¿ããèµ€
è¡çãæŽæµããããã®èµ€è¡çã«PH7.5ã0.15Mã®
ãªã³é žç·©è¡ççé£å¡©æ¶²ãå ããŠïŒïŒ æ¿åºŠã«èª¿è£œã
ããåãªã³é žç·©è¡ççé£å¡©æ¶²ã§2.5ïŒ æ¿åºŠã«èª¿è£œ
ããã°ã«ã¿ãŒã«ã¢ã«ããã溶液ãåèšèµ€è¡çæµ®é
液äžã«ããã®ïŒåã®ïŒå®¹ãå ããæ¹æããªãã宀
æž©ã§çŽïŒæéåå¿ãããèµ€è¡çãåºå®ãããã€ã
ã§ãã®æº¶æ¶²ãé å¿åé¢ããŠåºå®èµ€è¡çãåŸããã
ã«ççé£å¡©æ¶²ãçšãé å¿åé¢ã«ããæ°åæŽæµã
ãããã®åºå®èµ€è¡çãåèšãªã³é žç·©è¡æ¶²ã§ïŒïŒ æµ®
é液ã«èª¿è£œããããã«åãªã³é žç·©è¡ççé£å¡©æ¶²ã§
ïŒmgïŒdlã«èª¿è£œããã¿ã³ãã³é žæº¶æ¶²ãçéæ·»å ã
ãŠ30åéæ¹æããããã®æº¶æ¶²ãé å¿åé¢ããŠã¿ã³
ãã³é žåŠçåºå®èµ€è¡çãåŸãããã«ççé£å¡©æ¶²ã
çšãé å¿åé¢ã«ããæ°åæŽæµãããåŸãããã¿ã³
ãã³é žåŠåºå®èµ€è¡çã«åèšãªã³é žç·©è¡æ¶²ãå ãã
ïŒïŒ èµ€è¡çæµ®é液ãšããã ãã®èµ€è¡çæµ®é液ãšãå®æœäŸïŒã§åŸããã溶液
ãåèšãªã³é žç·©è¡ççé£å¡©æ¶²ã§èçœè³ªæ¿åºŠçŽ10ÎŒ
ïœïŒmlã«èª¿è£œãã液ãšãåéæ··åãã宀枩ã§60å
éæ¹æããŠæäœããããã®æ¶²ãé å¿åé¢ããŠæäœ
è¡çãåŸãããã«ççé£å¡©æ¶²ãçšãé å¿åé¢ã«ã
ãæ°åæŽæµãããåŸãããæäœèµ€è¡çã«ïŒïŒ æ£åžž
家å è¡æž å«æãªã³é žç·©è¡ççé£å¡©æ¶²ãå ããŠïŒïŒ
æµ®é液ãšããããã®æäœèµ€è¡çã¯PHAæ³ãå©çš
ãã蚺æè¬ã«äœ¿çšãããã å®æœäŸ ïŒ å®æœäŸïŒãããã¯å®æœäŸïŒã§åŸããã溶液ãPH
7.5ã0.05Mã®ãªã³é žç·©è¡æ¶²ã«æº¶è§£ããèçœè³ªæ¿
床ãïŒmgïŒmlã«èª¿è£œããããã®æ¶²10ÎŒã«ïŒããª
ããŠãŒãªãŒã® 125IâNa50ÎŒãå ããããã«ã¯
ãã©ãã³ïŒŽãåèšãªã³é žç·©è¡æ¶²ã«1.5mgïŒmlã®å²
åã«æº¶è§£ãã液ã10ÎŒå ããŠ30ç§éæ¹æããã
次ãã§ã¡ã¿éäºç¡«é žãããªãŠã ãåèšãªã³é žç·©è¡
液ã«ïŒmgïŒmlã®å²åã«æº¶è§£ãã液ã100ÎŒå ã
ãŠåå¿ãåæ¢ãããããšãŠåã«ãªãŠã ãåèšãªã³
é žç·©è¡æ¶²ã«10mgïŒmlã®å²åã«æº¶è§£ãã液100ÎŒ
ããã®åå¿æ¶²ã«å ãããã ã¡ã«ã»ãã¢ããã¯ã¹ïŒ§
â50ãçšããã²ã«éæ³ã«ãã 125Iæšèç©è³ªãš
125Iãšãåé¢ãããåŸããã 125Iæšèç©è³ªã®æ¯æŸ
å°èœã¯çŽ20ã60ÎŒCiïŒÎŒïœãšãªãããã® 125Iæšè
ç©è³ªã¯RIAæ³ãå©çšãã蚺æè¬ã«äœ¿çšãããã å®æœäŸ ïŒ å®æœäŸïŒãããã¯å®æœäŸïŒã§åŸããã溶液ãïŒ
ã10mgïŒmlïŒ0.05Mãªã³é žççé£å¡©ç·©è¡æ¶²äžïŒãš
ãªããŸã§æ¿çž®ãããã®0.1ã0.2mlã«å¯ŸããŠã¢ã«ã«
ãªãã¹ãã¢ã¿ãŒãŒïŒïŒmgïŒmlïŒã0.3mlã®å²åã§
æ·»å ãæ¹æããã次ã«2.5ïŒ ã°ã«ã¿ãŒã«ã¢ã«ãã
ã溶液50ÎŒãæ·»å ãã宀枩ã§30åéæ¹æããã
ããã0.05Mããªã¹å¡©é žç·©è¡æ¶²ïŒPH8.0ïŒã§äžæŒ
å€éæãã2000rpmã§10åéé å¿åé¢ããã®ã¡ã
ãã®äžæž ãé µçŽ æšèæåãšããŠEIAæ³ãå©çšãã
蚺æè¬ã«äœ¿çšãããã å®æœäŸ ïŒ PH7.5ã0.01Mã®ããªã¹å¡©é žç·©è¡æ¶²ïŒ0.15Mã®å¡©
åãããªãŠã ããã³0.1ïŒ ã®çªåãããªãŠã ãå«
ãïŒäžã«ã¢ã¬ããŒã¹ã1.2ïŒ æ¿åºŠã«ãªãããã«å
ç±æº¶è§£ããããã®ã¢ã¬ããŒã¹æº¶æ¶²80mlãçŽ56âãŸ
ã§å·åŽããå®æœäŸïŒã§åŸããã溶液20mlãæ·»å ã
ãŠæ¹æãããããããã©ã¹ããã¯å®¹åšäžã«æ³šå ¥ã
ãŠæŸå·ããåãïŒmmã®ã¢ã¬ããŒã¹ã²ã«å¹³æ¿ãšãªã
ãããã®å¹³æ¿ã«äžå®ã®ééããããŠçŽåŸïŒmmã®è©Š
æåããããã åŸããããã®ã¯SRIDæ³ãå©çšãã蚺æè¬ã«äœ¿
çšãããã
ãšããé«çã§ãããæ£åžžäŸè¡è ãåèçäŸã
åèçäŸã®ããããšãææãªå·®ã瀺ããã ïŒ ïŒ¡åèçäŸããã³ïŒ¢åèçäŸã«ãããŠã¯éœæ§
äŸã¯ãããã14.3ïŒ ã16.7ïŒ ã§ããããæ£åžžäŸ
è¡è ã®éœæ§äŸãšã®éã«ã¯ææãªå·®ãèªããããª
ãã ïŒ ééåèçæäœã¯æ£åžžäŸè¡è ã®çŽïŒïŒ ã«
ãã®ååšãèªããããã ïŒ å¹³ååé䟡ã«ãããŠããæ£åžžäŸè¡è è¡æž ã
åèçäŸè¡æž ãåèçäŸè¡æž ã®éã«ã¯ææãª
å·®ãèªããããªãããééåèçäŸè¡æž ã¯
æ£åžžäŸè¡è è¡æž ã«æ¯èŒããŠææïŒïœïŒ0.001ïŒ
ã«é«ãå€ã瀺ããã 以äžïŒä¹è³ïŒãããæ¬çºæç©è³ªãééåè
çæäœã«ã€ããŠäžè¬çã§ããããã€ééåè
çæäœã«ç¹ç°çãªæåã§ããããšãç¥ãããã å®éšäŸ ïŒ è©Š æ ééåèçæ£è ïŒäŸã®çµéè¡æž æ¹ æ³ çµéè¡æž ã«ã€ãééåèçæäœããã³
GPTã枬å®ãããééåèçæäœã¯æ¬çºæ
ç©è³ªãçšããŠå身赀è¡çåéåå¿æ³ã«ãã枬å®ã
ãã çµ æ çµæãå³ïŒä¹è³å³ïŒã«ç€ºããåå³ããæãããª
ããšããééåèçæäœã¯çºççŽåŸïŒGPT
ã®æ¥µæïŒã«ãããŠã¯è¡æž äžã«æ€åºãããªãããŸã
ã¯ããå ãã§ããããèæ©èœã®æ£åžžåïŒGPTã®
æžå°ïŒã«äŒŽãè¡æž äžã«åºçŸãããã®æäœäŸ¡ã¯ïŒã
ïŒå¹Žä»¥äžç¶æãããã®ã確èªããããããã®ããš
ãééåèçæäœã¯ééåèçã®èšºæã
ãã³äºåŸã®çµé芳å¯ã«æçšãªè¡äžããŒã«ãŒãšãªã
ã®ã§ãåœè©²æäœã«ã€ããŠäžè¬çã§ããããã€åœè©²
æäœã«ç¹ç°çã§ããæ¬çºæç©è³ªã¯ééåèç
ã«ã€ããŠã®æ£ç¢ºãªèšºæè¬ãæäŸãããã®ã§ããã
ãšãç¥ãããã 以äžã«èšèŒããå®æœäŸããã€ãŠæ¬çºæãããã«
詳现ã«èª¬æãã å®æœäŸ ïŒ ééåèçæ£è ã®åæ€èçŽïŒïœã现åãã
ããªã¹å¡©é žç·©è¡ççé£å¡©æ¶²ïŒ0.01MãPH7.5ïŒ20
mlãå ãããã¢ãžãã€ãºããã次ã«10000rpmã§
20åéé å¿ããŠããã®äžæž ããšããåé¢ç²Ÿè£œåã®
èãã¢ãžããŒãäžæž ãšããã ãããããããªã¹å¡©é žç·©è¡ççé£å¡©æ¶²
ïŒ0.01MãPH7.5ïŒã§å¹³è¡¡åããã»ãã¢ã¯ãªã«ïŒ³â
200ïŒãã¢ã«ãã·ã¢è£œïŒã®å å¡«ã«ã©ã ïŒ2.6Ã90cmïŒ
ã«èãã¢ãžããŒãäžæž 10mlãæ·»å ããããªã¹å¡©é ž
ç·©è¡ççé£å¡©æ¶²ïŒ0.01MãPH7.5ïŒã§æº¶åºãã
280nïœã®çŽ«å€éšåžåã§é£ç¶ã¢ãã¿ãŒããªããã
æå掻æ§ãæãã第äžããŒã¯ã®çžåœååãããŒã«
ããããªããæå掻æ§ã¯å¯å€©ã²ã«å åå¿ã«ããæ€
玢ãããããŒã«ããååã¯éå€éæ³ïŒã¢ãã³ã³
補PMâ10ïŒã«ãã€ãŠå å§æ¿çž®ããã 次ã«åŸãããæ¿çž®æ¶²ã«ã€ããŠãæ¯æäœãšããŠã»
ãã¢ã¯ãªã«ïŒ³â200ïŒãã¢ã«ãã·ã¢è£œïŒã®ä»£ããã«
ã»ãã¢ã¯ãªã«ïŒ³â300ïŒãã¢ã«ãã·ã¢è£œïŒã䜿çšã
ãŠäžèšèšèŒã«ããããšåæ§ã«æº¶åºæäœããããª
ããåã³éå€éæ³ã«ããå å§æ¿çž®ããã 次ã«åŸãããæ¿çž®æ¶²ïŒmlã«ã€ããŠèç³æ¿åºŠåŸé
é å¿åé¢ïŒ24000rpmã16æéïŒããããªã€ãã
æ¿åºŠåŸé ã¯ïŒã60ïŒ ïŒïœïŒïœïŒã®ç¯å²ã«ãããŠã
ããªããïŒïŒ ã15ïŒ ã25ïŒ ã35ïŒ ã§ã¯å10mlã«ã
45ïŒ ã60ïŒ ã§ã¯åïŒmlã«ãªãããã«äœè£œããæ¿çž®
液ãæäžéšã«æ·»å ãããåŠçåŸããŠãŒãåºãã
2.5mlïŒtubeã®å²åã§ååããæå掻æ§ãæãã
èç³æ¿åºŠ25ã40ïŒ çžåœååãããŒã«ãããããŒã«
ããååã«ã€ããŠããªã¹å¡©é žç·©è¡ççé£å¡©æ¶²
ïŒ0.01MãPH7.5ïŒã§éæããããªããéå€éæ³
ïŒã¢ãã³ã³è£œPMâ10ïŒã«ããå å§æ¿çž®ããã 次ã«åŸãããæ¿çž®æ¶²ã«ã€ããŠå¡©åã»ã·ãŠã 平衡
å¯åºŠåŸé é å¿åé¢ïŒ40000rpmã20æéïŒããã
ãªã€ãã1.00ã1.50ïœïŒcm3ã®å¯åºŠåŸé ç¯å²ã«ãã
ãŠå4.5mlãäœè£œããæ¿çž®æ¶²ãæäžéšã«æ·»å ããã
åŠçåŸãããŠãŒãäžå±€ããã0.2mlïŒtubeã®å²å
ã§ååããæå掻æ§ãæããå¡©åã»ã·ãŠã å¯åºŠ
1.15ã1.25ïœïŒcm3çžåœååãããŒã«ããããªãå
ååã®æ¯éã¯ã¢ããã®å±æèšã§æž¬å®ãããããŒã«
ããååã«ã€ããŠã®ããªã¹å¡©é žç·©è¡ççé£å¡©æ¶²
ïŒ0.01MãPH7.5ïŒã§éæããã ããã«åŸããã溶液ã«å«ãŸããç©è³ªã®çååŠç
æ§ç¶ã¯äžèšã®ããšãã§ãããå®éšäŸïŒãïŒãïŒã
ïŒã®åå®éšã«ãããæ¬çºæç©è³ªãšããŠäœ¿çšããã ååé 150äžä»¥äžïŒã²ã«éæ³ïŒ æ²éå®æ°ïŒ10-13ïŒ 51.5SïŒè¶ é å¿åææ³ïŒ æµ®äžå¯åºŠïŒïœïŒcm3ïŒ 1.15ã1.25ïŒå¡©åã»ã·ãŠã
äžããã³èåã«ãªãŠã äžïŒ ç²åçŽåŸïŒïœïœïŒ 26ã37 é»æ°ç移å床
α2âα1ã°ãããªã³é åïŒã¢ã¬ããŒã¹ã²ã«äžïŒ ãŸããæ¬çºæç©è³ªã«å¯ŸããæäœïŒééåè
çæ£è ã®å埩æè¡æž ç±æ¥ïŒãçšæãããããšæ¬çº
æç©è³ªãšãè©Šéšç®¡å ã§æ··åãã37âã§60åéã€ã³
ããŠããŒãããã€ã¥ããŠïŒâã§äžæŒå€é眮ãã
10000rpmã§20åéé å¿åé¢ããããã®çµæãæ¬
çºæç©è³ªã¯æåæäœè€åç©ã®æ²æž£ãšããŠååã
ãããããé»é¡èŠ³å¯ãããšãçŽåŸçŽ26ã37nïœã®
ç圢ç²åãçžäºã«åéããŠããã®ãã¿ãããã å®æœäŸ ïŒ å®æœäŸïŒã§åŸããã溶液ã«ããã€ã³ãå®å šã¢ãž
ãŠãã³ããïŒïŒïŒã®æ¯ã«å ããŠä¹³åãããä¹³å液
0.5mlããŠãµã®ã®èéšç®äžãç®å ããã³è¶³è¹ éšã«
åå²æ³šå°ããŠå ç«ãããïŒé±éåŸã«åéã®ä¹³å液
ãåæ§ã«ããŠè¿œå å ç«ããããã«ååã®å ç«ãã
ïŒã«æåŸã«åéã®ä¹³å液ãå床远å å ç«ãããæ
åŸã®å ç«ããïŒé±éåŸããæ°åã«ããã€ãŠæ¡è¡
ããè¡æž ãåé¢ããããã®è¡æž ã«åéã®æ£åžžãã
èè¡æž ãå ãã37âã§ïŒæéãããã«ïŒâã§ïŒå€
æŸçœ®ãããããã10000rpmã§10åéé å¿åé¢ãã
äžæŸæ¶²ãæ¡åãããåŸãããæè¡æž äžã®æäœãç¡«
é žã¢ã³ã¢ããŠã ã«ããå¡©æããã³DEAEã»ã«ããŒ
ãºã«ããã«ã©ã ã¯ãããã°ã©ãã€ãŒã«ãã粟補
ããã€ãã§PH9.0ã0.1Mã®ãã«ãã¿ãŒã«ç·©è¡æ¶²ã«
溶解ããèçœè³ªæ¿åºŠã10mgïŒmlã«èª¿è£œããããã
ãããã ã·ã¢ã³æŽ»æ§åã»ãã¢ããŒãº4Bã²ã«ã«å
éå ããïŒâã§24æéåå¿ããããã€ãã§æªåå¿
ã®èçœè³ªãPH7.5ã0.05Mã®ãªã³é žç·©è¡ççé£å¡©
液ã§æŽæµé€å»ããåŸããããçŽåŸ1.5cmãé·ã20
cmã®ã«ã©ã ã«å å¡«ããããã®ã«ã©ã ã«å®æœäŸïŒã§
åŸããã溶液ãæ·»å ãããåèšãªã³é žç·©è¡ççé£
塩液ãçšããŠæªåå¿ç©ãæŽæµé€å»ããåŸã解é¢å€
ãã«ã©ã ã«å ãã溶åºãããããæ¡åãã溶åºæ¶²
ãèžçæ°Žã§éæããŠè§£é¢å€ãé€å»ããã€ãã§ã¢ã
ã³ã³ãã€ã€ãããŒXMâ50ã«ãã€ãŠæ¿çž®ãããã
ãã«åŸããã溶液ã¯å®æœäŸïŒãïŒãïŒã®PHAæ³ã
RIAæ³ãEIAæ³ãå©çšãã蚺æè¬ã補é ãããã
ã®ééåèçé¢é£æåã«äœ¿çšãããã å®æœäŸ ïŒ ãããžè¡æ¶²ãé å¿ç®¡ã«ãšããççé£å¡©æ¶²ãçšã
ãŠ2000rpmã§10åéã®é å¿åé¢ãïŒåç¹°è¿ããèµ€
è¡çãæŽæµããããã®èµ€è¡çã«PH7.5ã0.15Mã®
ãªã³é žç·©è¡ççé£å¡©æ¶²ãå ããŠïŒïŒ æ¿åºŠã«èª¿è£œã
ããåãªã³é žç·©è¡ççé£å¡©æ¶²ã§2.5ïŒ æ¿åºŠã«èª¿è£œ
ããã°ã«ã¿ãŒã«ã¢ã«ããã溶液ãåèšèµ€è¡çæµ®é
液äžã«ããã®ïŒåã®ïŒå®¹ãå ããæ¹æããªãã宀
æž©ã§çŽïŒæéåå¿ãããèµ€è¡çãåºå®ãããã€ã
ã§ãã®æº¶æ¶²ãé å¿åé¢ããŠåºå®èµ€è¡çãåŸããã
ã«ççé£å¡©æ¶²ãçšãé å¿åé¢ã«ããæ°åæŽæµã
ãããã®åºå®èµ€è¡çãåèšãªã³é žç·©è¡æ¶²ã§ïŒïŒ æµ®
é液ã«èª¿è£œããããã«åãªã³é žç·©è¡ççé£å¡©æ¶²ã§
ïŒmgïŒdlã«èª¿è£œããã¿ã³ãã³é žæº¶æ¶²ãçéæ·»å ã
ãŠ30åéæ¹æããããã®æº¶æ¶²ãé å¿åé¢ããŠã¿ã³
ãã³é žåŠçåºå®èµ€è¡çãåŸãããã«ççé£å¡©æ¶²ã
çšãé å¿åé¢ã«ããæ°åæŽæµãããåŸãããã¿ã³
ãã³é žåŠåºå®èµ€è¡çã«åèšãªã³é žç·©è¡æ¶²ãå ãã
ïŒïŒ èµ€è¡çæµ®é液ãšããã ãã®èµ€è¡çæµ®é液ãšãå®æœäŸïŒã§åŸããã溶液
ãåèšãªã³é žç·©è¡ççé£å¡©æ¶²ã§èçœè³ªæ¿åºŠçŽ10ÎŒ
ïœïŒmlã«èª¿è£œãã液ãšãåéæ··åãã宀枩ã§60å
éæ¹æããŠæäœããããã®æ¶²ãé å¿åé¢ããŠæäœ
è¡çãåŸãããã«ççé£å¡©æ¶²ãçšãé å¿åé¢ã«ã
ãæ°åæŽæµãããåŸãããæäœèµ€è¡çã«ïŒïŒ æ£åžž
家å è¡æž å«æãªã³é žç·©è¡ççé£å¡©æ¶²ãå ããŠïŒïŒ
æµ®é液ãšããããã®æäœèµ€è¡çã¯PHAæ³ãå©çš
ãã蚺æè¬ã«äœ¿çšãããã å®æœäŸ ïŒ å®æœäŸïŒãããã¯å®æœäŸïŒã§åŸããã溶液ãPH
7.5ã0.05Mã®ãªã³é žç·©è¡æ¶²ã«æº¶è§£ããèçœè³ªæ¿
床ãïŒmgïŒmlã«èª¿è£œããããã®æ¶²10ÎŒã«ïŒããª
ããŠãŒãªãŒã® 125IâNa50ÎŒãå ããããã«ã¯
ãã©ãã³ïŒŽãåèšãªã³é žç·©è¡æ¶²ã«1.5mgïŒmlã®å²
åã«æº¶è§£ãã液ã10ÎŒå ããŠ30ç§éæ¹æããã
次ãã§ã¡ã¿éäºç¡«é žãããªãŠã ãåèšãªã³é žç·©è¡
液ã«ïŒmgïŒmlã®å²åã«æº¶è§£ãã液ã100ÎŒå ã
ãŠåå¿ãåæ¢ãããããšãŠåã«ãªãŠã ãåèšãªã³
é žç·©è¡æ¶²ã«10mgïŒmlã®å²åã«æº¶è§£ãã液100ÎŒ
ããã®åå¿æ¶²ã«å ãããã ã¡ã«ã»ãã¢ããã¯ã¹ïŒ§
â50ãçšããã²ã«éæ³ã«ãã 125Iæšèç©è³ªãš
125Iãšãåé¢ãããåŸããã 125Iæšèç©è³ªã®æ¯æŸ
å°èœã¯çŽ20ã60ÎŒCiïŒÎŒïœãšãªãããã® 125Iæšè
ç©è³ªã¯RIAæ³ãå©çšãã蚺æè¬ã«äœ¿çšãããã å®æœäŸ ïŒ å®æœäŸïŒãããã¯å®æœäŸïŒã§åŸããã溶液ãïŒ
ã10mgïŒmlïŒ0.05Mãªã³é žççé£å¡©ç·©è¡æ¶²äžïŒãš
ãªããŸã§æ¿çž®ãããã®0.1ã0.2mlã«å¯ŸããŠã¢ã«ã«
ãªãã¹ãã¢ã¿ãŒãŒïŒïŒmgïŒmlïŒã0.3mlã®å²åã§
æ·»å ãæ¹æããã次ã«2.5ïŒ ã°ã«ã¿ãŒã«ã¢ã«ãã
ã溶液50ÎŒãæ·»å ãã宀枩ã§30åéæ¹æããã
ããã0.05Mããªã¹å¡©é žç·©è¡æ¶²ïŒPH8.0ïŒã§äžæŒ
å€éæãã2000rpmã§10åéé å¿åé¢ããã®ã¡ã
ãã®äžæž ãé µçŽ æšèæåãšããŠEIAæ³ãå©çšãã
蚺æè¬ã«äœ¿çšãããã å®æœäŸ ïŒ PH7.5ã0.01Mã®ããªã¹å¡©é žç·©è¡æ¶²ïŒ0.15Mã®å¡©
åãããªãŠã ããã³0.1ïŒ ã®çªåãããªãŠã ãå«
ãïŒäžã«ã¢ã¬ããŒã¹ã1.2ïŒ æ¿åºŠã«ãªãããã«å
ç±æº¶è§£ããããã®ã¢ã¬ããŒã¹æº¶æ¶²80mlãçŽ56âãŸ
ã§å·åŽããå®æœäŸïŒã§åŸããã溶液20mlãæ·»å ã
ãŠæ¹æãããããããã©ã¹ããã¯å®¹åšäžã«æ³šå ¥ã
ãŠæŸå·ããåãïŒmmã®ã¢ã¬ããŒã¹ã²ã«å¹³æ¿ãšãªã
ãããã®å¹³æ¿ã«äžå®ã®ééããããŠçŽåŸïŒmmã®è©Š
æåããããã åŸããããã®ã¯SRIDæ³ãå©çšãã蚺æè¬ã«äœ¿
çšãããã
å³ïŒã¯å®éšäŸïŒçµæã®é
ã«èšèŒã®å³ïŒã«çžåœ
ãããã€ã¯ããªã¯ã¿ãããŒæ³ã«ãã€ãŠå¯å€©ã²ã«å
åå¿ããããå Žåã«çããæ²éç·ã®çæç¶æ³ã瀺
ãæš¡åŒå³ã§ãããå³äžïŒ¡ã¯æ¬çºæç©è³ªãã¯é
éåèçå埩ææ£è ã®è¡æž ãã®äžãã¯åãã®
äºãã¯é »å茞è¡æŽã®ããæ£è ã®è¡æž ãã¯æ£åžž
ããè¡æž ãã¯æ£åžžããèãã¢ãžããŒãäžæž ãã
ãããã¹ãããããé 眮ãšãªã¢ã瀺ãã å³ïŒä¹è³å³ïŒã¯å®éšäŸïŒã®çµæã®é ã«èšèŒã®å³
ïŒä¹è³å³ïŒã«çžåœããééåèçæ£è ã«ãã
ãééåèçæäœïŒãå°ç·ïŒããã³GPTïŒâ
å°ç·ïŒã®çµæçæšç§»ã瀺ãã
ãããã€ã¯ããªã¯ã¿ãããŒæ³ã«ãã€ãŠå¯å€©ã²ã«å
åå¿ããããå Žåã«çããæ²éç·ã®çæç¶æ³ã瀺
ãæš¡åŒå³ã§ãããå³äžïŒ¡ã¯æ¬çºæç©è³ªãã¯é
éåèçå埩ææ£è ã®è¡æž ãã®äžãã¯åãã®
äºãã¯é »å茞è¡æŽã®ããæ£è ã®è¡æž ãã¯æ£åžž
ããè¡æž ãã¯æ£åžžããèãã¢ãžããŒãäžæž ãã
ãããã¹ãããããé 眮ãšãªã¢ã瀺ãã å³ïŒä¹è³å³ïŒã¯å®éšäŸïŒã®çµæã®é ã«èšèŒã®å³
ïŒä¹è³å³ïŒã«çžåœããééåèçæ£è ã«ãã
ãééåèçæäœïŒãå°ç·ïŒããã³GPTïŒâ
å°ç·ïŒã®çµæçæšç§»ã瀺ãã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ ééåèçåæ€èããã®åé¢ç²Ÿè£œã«ãã€
ãŠåŸãããäžèšã®çååŠçæ§ç¶ãæããéé
åèçé¢é£æåã ååé 150äžä»¥äžïŒã²ã«éæ³ïŒ æ²éå®æ°ïŒ10-13ïŒ 51.5SïŒè¶ é å¿åææ³ïŒ æµ®äžå¯åºŠïŒïœïŒcm3ïŒ 1.15ã1.25ïŒå¡©åã»ã·ãŠã
äžããã³èåã«ãªãŠã äžïŒ ç²åçŽåŸïŒïœïœïŒ 26ã37 é»æ°ç移å床
α2âα1ã°ãããªã³é åïŒã¢ã¬ããŒã¹ã²ã«äžïŒ ïŒ ééåèçåæ€èããã®åé¢ç²Ÿè£œã«ãã€
ãŠåŸãããäžèšã®çååŠçæ§ç¶ãæããéé
åèçé¢é£æåãäž»èŠãªæ§ææåãšããŠå«æãã
ééåèç蚺æè¬ã ååé 150äžä»¥äžïŒã²ã«éæ³ïŒ æ²éå®æ°ïŒ10-13ïŒ 51.5SïŒè¶ é å¿åææ³ïŒ æµ®äžå¯åºŠïŒïœïŒcm3ïŒ 1.15ã1.25ïŒå¡©åã»ã·ãŠã
äžããã³èåã«ãªãŠã äžïŒ ç²åçŽåŸïŒïœïœïŒ 26ã37 é»æ°ç移å床
α2âα1ã°ãããªã³é åïŒã¢ã¬ããŒã¹ã²ã«äžïŒ
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56083736A JPS57198867A (en) | 1981-06-02 | 1981-06-02 | Non-a, non-b hepatitis related antigen and diagnostic therefor |
| CA000404236A CA1184846A (en) | 1981-06-02 | 1982-06-01 | Non-a, non-b hepatitis-associated antigen and diagnostic reagent |
| EP82104830A EP0066296B1 (en) | 1981-06-02 | 1982-06-02 | Non-a, non-b hepatitis-associated antigen, a conjugate therof and diagnostic reagent containing same |
| DE8282104830T DE3267389D1 (en) | 1981-06-02 | 1982-06-02 | Non-a, non-b hepatitis-associated antigen, a conjugate therof and diagnostic reagent containing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56083736A JPS57198867A (en) | 1981-06-02 | 1981-06-02 | Non-a, non-b hepatitis related antigen and diagnostic therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57198867A JPS57198867A (en) | 1982-12-06 |
| JPH0250426B2 true JPH0250426B2 (ja) | 1990-11-02 |
Family
ID=13810807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56083736A Granted JPS57198867A (en) | 1981-06-02 | 1981-06-02 | Non-a, non-b hepatitis related antigen and diagnostic therefor |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0066296B1 (ja) |
| JP (1) | JPS57198867A (ja) |
| CA (1) | CA1184846A (ja) |
| DE (1) | DE3267389D1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021245697A1 (en) | 2020-06-01 | 2021-12-09 | Celagenex Research (India) Pvt. Ltd. | Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2502154A1 (fr) * | 1981-03-30 | 1982-09-24 | Trepo Christian | Procede de preparation d'antigenes de l'hepatite virale nanb, et application a la realisation d'un reactif permettant le diagnostic et le pronostic des infections provoquees par les virus des hepatites virales |
| JPS58183629A (ja) * | 1982-04-21 | 1983-10-26 | Eisai Co Ltd | éïœéïœåèçé¢é£ã¢ãã¯ããâã«æäœããã³èšºæè¬ |
| EP0093438B1 (en) * | 1982-05-05 | 1988-07-20 | Louisiana State University and Agricultural and Mechanical College | Non-a, non-b hepatitis antigen |
| US4673634A (en) * | 1985-03-08 | 1987-06-16 | The United States Of America As Represented By The Department Of Health And Human Services | Purified antigen from non-A, non-B hepatitis causing factor |
| FR2597606B1 (fr) * | 1986-04-16 | 1989-10-06 | Pasteur Institut | Nouveau reactif pour la detection d'hepatites virales non a non b et procede de diagnostic de telles hepatites par voie immunoenzymatique |
| NZ222465A (en) * | 1986-11-07 | 1992-11-25 | Pasteur Institut | Nanb (non a, non b hepatitis viral) antigen |
| FR2606515B1 (fr) * | 1986-11-07 | 1992-02-21 | Pasteur Institut | Procede pour l'isolement d'un nouvel agent viral et de l'antigene qui lui est associe, agent viral et antigene obtenus par ce procede et procede de detection dudit antigene a l'aide d'un reactif immunologique approprie |
| DE3744242A1 (de) * | 1987-02-20 | 1989-07-06 | Seelig Renate | Virusantigen, verfahren zu seiner gewinnung und anwendung in diagnose und therapie (impfstoff) |
| US5032511A (en) * | 1987-03-31 | 1991-07-16 | Mitsubishi Kasei Corporation | DNA fragments coding for antigens specific to non-A non-B hepatitis, expression vectors containing said DNA fragments, transformants and process for producing said antigens |
| US5350671A (en) * | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
| US5191064A (en) * | 1988-09-30 | 1993-03-02 | The Research Foundation For Microbial Diseases (Osaka University) | Non-a, non-b hepatitis virus antigen peptide |
| US7166287B1 (en) | 1989-12-18 | 2007-01-23 | Glaxo Wellcome Inc. | Viral agent |
| SE9004010D0 (sv) | 1989-12-18 | 1990-12-17 | Wellcome Found | Viralt medel |
| EP0602290B1 (en) * | 1992-12-04 | 1999-08-25 | ConjuChem, Inc. | Antibody-conjugated Hepatitis B surface antigen and use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4356164A (en) * | 1979-05-21 | 1982-10-26 | Govt. of the U.S., as represented by the Secretary, Dept. of Health & Human Services | Detection of non-A, non-B hepatitis associated antigen |
| FR2502154A1 (fr) * | 1981-03-30 | 1982-09-24 | Trepo Christian | Procede de preparation d'antigenes de l'hepatite virale nanb, et application a la realisation d'un reactif permettant le diagnostic et le pronostic des infections provoquees par les virus des hepatites virales |
-
1981
- 1981-06-02 JP JP56083736A patent/JPS57198867A/ja active Granted
-
1982
- 1982-06-01 CA CA000404236A patent/CA1184846A/en not_active Expired
- 1982-06-02 EP EP82104830A patent/EP0066296B1/en not_active Expired
- 1982-06-02 DE DE8282104830T patent/DE3267389D1/de not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021245697A1 (en) | 2020-06-01 | 2021-12-09 | Celagenex Research (India) Pvt. Ltd. | Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57198867A (en) | 1982-12-06 |
| DE3267389D1 (en) | 1985-12-19 |
| EP0066296A2 (en) | 1982-12-08 |
| EP0066296B1 (en) | 1985-11-13 |
| EP0066296A3 (en) | 1983-03-30 |
| CA1184846A (en) | 1985-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5086002A (en) | Erythrocyte agglutination assay | |
| Imai et al. | A receptor for polymerized human and chimpanzee albumins on hepatitis B virus particles co-occurring with HBeAg | |
| Benedict et al. | Physical properties of antibody to bovine serum albumin as demonstrated by hemagglutination | |
| Solomon et al. | A âmonoclonalâ type, low molecular weight protein related to γM-macroglobulins | |
| US4894347A (en) | Erythrocyte agglutination assay | |
| JPH0250426B2 (ja) | ||
| EP0092249B1 (en) | Non-a, non-b hepatitis-associated monoclonal antibody and diagnostic reagent | |
| US4871659A (en) | Reagent for detecting non-A, non-B viral hepatitis (NANBH) and an immunoenzymatic method for detecting NANBH antigens in fecal extracts | |
| KR100500793B1 (ko) | Cíê°ìŒë°ìŽë¬ì€ê°ìŒìŠì§ëšìœ | |
| JPH0250427B2 (ja) | ||
| US4132767A (en) | Preparation of α-L antibody, purification of α-L antigen and reagent for detection of α-L antibody and α-L antigen | |
| KR930012113B1 (ko) | HBc íìì ì ì¬ë°©ë² ë° ì ì ë HBc íìì ìŽì©í HBc í첎ì ìž¡ì ë°©ë² | |
| AU596404B2 (en) | Competitive elisa for the detection of antibodies | |
| EP0321604B1 (en) | Antigen-antibody complex and method of using same | |
| EP0308242B1 (en) | Agglutination assay | |
| JPS6231301B2 (ja) | ||
| JP3864194B2 (ja) | è€æ°ã®äºåãååšããæåã®å ±éæå決å®åºã«ç¹ç°çãªæäœã®æž¬å®æ³ãªãã³ã«æž¬å®è©Šè¬ | |
| CA2069546C (en) | Diagnostic method | |
| JPH06502075A (ja) | åèçãŠã€ã«ã¹æäœ | |
| JP2957195B2 (ja) | åèçãŠã€ã«ã¹æäœæ€åºã·ã¹ãã | |
| JPH073427B2 (ja) | ïœïœæäœã®æž¬å®æ³ | |
| JPH0382962A (ja) | åèçãŠã£ã«ã¹ïŒ£ïœïœïœ æåã«å¯Ÿããæäœã®æ€åºæ¹æ³ | |
| JPH06130060A (ja) | ç²åå ç«æž¬å®çšç²åã®é«æ¯éåæ³ | |
| JPH02120664A (ja) | å ç«åŠçæåæ€åºæ³ | |
| IE61639B1 (en) | Agglutination assay |